论文信息 - Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C - 字舞流文

Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C

V. Villanacci | F. Castelli | I. Izzo | M. Salemme | L. Biasi | S. Casari | P. Zanotti | C. Chirico | E. Festa

[1] M. Neurath,et al. Advances in hepatitis C therapy: What is the current state - what come's next? , 2016, World journal of hepatology.

[2] Kisha Mitchell,et al. Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C , 2015, ACG case reports journal.

[3] K. Sheahan,et al. Iatrogenic pathology of the intestines , 2015, Histopathology.

[4] L. Croner,et al. Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohn's Disease, and Ulcerative Colitis Patients , 2013, Inflammatory bowel diseases.

[5] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[6] M. Cho,et al. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report. , 2012, World journal of gastroenterology.

[7] R. Myers,et al. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. , 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.